Skip to Main Content

Paper Details

Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1).
J Infect Dis
3
2023
Author NameAffiliation
Pavitra RoychoudhuryCenter for Innate Immunity and Immune Disease, University of Washington
Pavitra RoychoudhuryFred Hutchinson Cancer Center
Keith R JeromeCenter for Innate Immunity and Immune Disease, University of Washington
Keith R JeromeFred Hutchinson Cancer Center
Renee C IretonCenter for Innate Immunity and Immune Disease, University of Washington
Gregory Camus
Alexander L GreningerCenter for Innate Immunity and Immune Disease, University of Washington
Alexander L GreningerFred Hutchinson Cancer Center
  • 1 - 8

Datasets

Release 1.2